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Background: Quality of life is an important parameter in the evaluation of quality and outcome of health care and treatment, especially in patients
with chronic disorders. The aim of this study was to assess the validity and reliability of the Danish version of the revised disease-specific health-
related quality of life questionnaire for adolescents and adults with cystic fibrosis (CFQ-R14+).
Methods: A total of 196 cystic fibrosis (CF) patients completed the CFQ-R14+ (response rate 71%). Forced expiratory volume in 1 s in percentage
of predicted (FEV1%) and body mass index (BMI) were included as measures of health status.
Results: Internal consistency coefficients ranged from 0.54 to 0.95. Eight out of the twelve scales had alpha coefficients above 0.7. Test–retest
correlations ranged from 0.42 to 0.88 and they were significant in eight scales. All the CFQ-R+14 scales except the digestive symptoms scale
discriminated significantly (pb0.05) between patients with mild, moderate, and severe disease. Nine out of the twelve scales discriminated
significantly (pb0.05) between nourished (BMI≥19) and malnourished (BMIb19) patients. Significant differences between participants and non-
responders were found for age, sex and FEV1 (higher age, more males and lower FEV1 among non-responders). All of the scales met standards for
floor effects (b15% of the responders with the lowest score) but five of the scales failed to meet standards for ceiling effects (N15% of the
responders with the highest score).
Conclusion: The Danish CFQ-R14+ is a reliable and valid instrument for measuring the health-related quality of life in Danish adolescents and
adults with CF, though with the exception from a few of its subscales.
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Cystic Fibrosis (CF) is a chronic, progressive and fatal
disease. Life expectancy has increased substantially in the
recent decades due to early diagnosis and improved treatment
[1]. CF affects many organs; the burden of treatment is heavy⁎ Corresponding author. Department of Paediatrics, Cystic Fibrosis Centre,
Aarhus University Hospital, Skejby, Brendstrupgaardsvej 100, DK-8200 Aarhus
N., Denmark. Tel.: +45 89496781; fax: +45 89496790.
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1569-1993/$ - see front matter © 2008 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2008.06.006for the patients and for most the burden grows with age.
Traditional measures of clinical status such as lung function and
body mass index do not capture all the aspects of the disease [2].
Health-related quality of life (HRQOL) questionnaires evaluate
the impact of a disease on the patient's daily life rather than just
the physical status. The HRQOL questionnaires are patient
centered and provide information about the patient's own as-
sessment of his physical, functional, social, emotional and
psychological condition as well as his daily functioning and
well-being. This information is essential when assessing the
impact of a chronic disease on a patient's life, in the evaluationd by Elsevier B.V. All rights reserved.
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treatment and care. They ought to be included routinely in
clinical trials and in medical cost benefit analyses. However, the
questionnaires on quality of life are not sensitive enough and
not designed to capture disease-specific problems [3–9].
About ten years ago disease-specific quality of life ques-
tionnaires on other chronic diseases such as asthma and diabetes
were developed [10,11]. In 1997, a CF-specific quality of life
questionnaire was developed in France (CFQ) [12] and in 2000
it was translated and validated in English and then modified
(CFQ-R) [7]. In 2000 another questionnaire was developed in
the United Kingdom (CFQoL) [5]. The advantage of the CFQ-R
is that versions of the questionnaire for children with CF from
the age of six and their parents were developed, which provided
the opportunity to conduct long-term studies. A patient's quality
of life evolves over time due to life events, illness progress,
coping abilities, development of treatment, and cultural changes
[13]. Therefore, it is important to monitor the patient's quality
of life over time. A specific tool like the CFQ-R can provide a
broader assessment of the CF patient's life situation and can be
very useful in the collaboration between the patient and the CF
team.
The revised cystic fibrosis quality of life questionnaire for
adolescents and adults (CFQ-R14+) [14] is now translated into
several languages [15] and widely used. It allows cross-cultural
studies [16] and multicentre studies where quality of life is often
used to assess health care outcome in addition to conventional
measures. Only a few of the translated CFQ-R14+ question-
naires have been psychometrically validated and published [14,
17,18]. The validation of the American, the Dutch and the
German versions all demonstrated that the CFQ-R14+ is a
reliable and valid tool for measuring HRQOL in CF patients.
They demonstrated Chronbach's α (reliability) as follows:
American: 0.67–0.94, German: 0.71–0.94, Dutch: 0.43–0.92
and test–retest stability as follows: American: 0.45–0.90,
Dutch: 0.72–0.98. All of the studies showed good differentia-
tion between mild, moderate and severe disease.
The aim of the current study was to assess the validity and
reliability of the Danish version of the CFQ-R+14.
2. Methods
2.1. Measures
The CFQ-R+14 consists of 49 self-reported items within
twelve domains: physical functioning [8], vitality [4], emotional
functioning [5], eating disturbances [3], treatment burden [3],
general health perception [3], social functioning [6], body
image [3], role limitations [4], weight problems [1], respiratory
symptoms [6] and digestive symptoms [3]. The possibilities for
answer are on a four point scale rating frequency, difficulty or
truth and selecting one out of four statements that would best
describe the patient's situation. The scores range from 0 to 100
and the higher the score, the higher is the patient's quality of
life.
A method of assessing whether measures can differentiate
between patients with various degrees of disease severity is todivide the patients on the basis of percentage of predicted forced
expiratory volume in 1 s (FEV1%) [5]. The patients were divided
into three disease severity groups: mild (FEV1%≥71), moderate
(FEV1% 41–70) and severe (FEV1%≤40). Since severity of the
disease is related to older age the patients were divided into age
groups: adolescents (14–17 years), young adults (18–25 years)
and adults (N25 years). As nutritional status might play a role in
the evaluation of the disease severity of the CF patient, the
patients were also categorized according to their nutritional status
(BMI≥19=nourished, BMIb19=malnourished) [17,19].
2.2. Translation
Linguistic validation was made in accordance with interna-
tional guidelines [20] and the specific recommendations for the
CFQ-R+14 [7]. At first, two independent translators made a
forward translation from English to Danish. Two CF pediatri-
cians reviewed these translations and the translations were
merged to one raw translation. Two individual translators made
a backward translation from Danish to English and it was com-
pared with the original English version of the questionnaire. The
second raw translation into Danish was made. Several adult CF
patients critically read the second version of the raw translation
and after a few adjustments were made to form the final Danish
CFQ-R+14 aimed at teenagers and adults.
2.3. Participants and procedures
The CFQ-R+14 was mailed to all Danish CF patients above
the age of 13 (N=278) in August 2006.
A total of 196 patients with a confirmed diagnosis of CF
from the two Danish CF centers filled in the CFQ-R+14. The
response rate was 71%. A group of clinically stable patients
with no change in their basic treatment (N=14) completed the
questionnaire again 10–14 days later. Mean age of the par-
ticipants was 26 years (range 14–52) and 53.1% of the par-
ticipants were female (104 females, 92 males).
Data on BMI and FEV1% were extracted from the national
CF registry. Sixteen of the participants were left out of the
validity calculations because their data from the national CF
registry were too old (N6 months). Mean number of days
between the clinical data and the CFQ-R+14 was 16 days (range
0–182).
A total of 180 participants had relevant data from the CF
registry. Their mean FEV1 was 71.9% predicted (SD 25.4,
range 24.7–132.1%), (mild N=95, moderate N=60 and severe
N=24).
Mean BMI was 20.9 (SD 3.3, range 13–35), (nourished
N=131 and malnourished N=49). Mean age was 25 years (SD
8.5, range 14–48) (40 adolescents, 56 young adults and 84
adults); 53.9%were female (97 females, 83males). Therewere no
significant differences between participants and non-responders
concerning BMI (participantsM=20.9, SD=3.3; non-responders
M=20.9, SD=3.6; t=−0.08, p=0.94). There were significant
differences in age (participants: M=25.5, SD=8.5; non-respon-
ders M=27.9, SD=10.0; t=2.00, p=0.047) and FEV1 (partici-
pants M=71.9, SD=25.4, non-responders M=63.8, SD=26.3;
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(70.7%) (Pearson Chi-Square 12.77, pb0).
2.4. Ethics
In accordance with the regulations of The National Danish
Ethics Committee questionnaire-based projects do not have to
be notified. The project is registered at The Danish Data
Protection Agency.
3. Statistical analyses
3.1. Patients
The reliability calculations were made on the sample of 196
participants filling in the CFQ-R14+ questionnaire. The validity
calculations were made on the sample of 180 participants who
had relevant data from the CF registry and had filled in the
CFQ-R+14.
Independent sample t-tests were conducted to test for
differences in age, BMI and FEV1. A chi-square test for inde-
pendence was conducted to explore the relationship between
sex and responder/non-responder.
3.2. Reliability
The internal consistency or reliability of each scale was
calculated using Chronbach's α. The purpose was to assess the
association between the items and their scales, respectively. A
minimum level of 0.7 is recommended [21].
Test–retest reliability was tested on a medically stable group
of patients (N=14) using Spearman's correlation. Their mean
age was 27 years (SD 9.4, range 17–42), mean BMI 20.4 (SD
2.5, range 9–17) and mean FEV1% was 78.6 (SD 32.3, range
18.7–103.0); 50% were males. The purpose was to assess the
stability of the scores over time. For test–retest with one to two
weeks interval a correlation higher than 0.80 suggests adequate
stability [22].Table 1
Internal consistencies (Chronbach's α), test–retest (Spearman's correlation) and ceil
No of
items
Chronbach's α
coefficient
Test–retest Spearm
correlation
Physical functioning 8 0.95 0.68
Role limitations 4 0.81 0.52
Vitality 4 0.78 0.53
Emotional functioning 5 0.76 0.84
Social functioning 6 0.54 0.42
Body image 3 0.67 0.45
Eating disturbances 3 0.91 0.88
Treatment burden 3 0.72 0.70
Health perceptions 3 0.87 0.84
Weight problems 1 0.83
Respiratory symptoms 6 0.84 0.70
Digestive symptoms 3 0.64 0.61
* Correlation is significant at the 0.01 level (2-tailed).
** Correlation is significant at the 0.05 level (2-tailed).The floor and ceiling effects were calculated for each scale.
Those with floor and ceiling effect b15% (b15% of the re-
sponders with the lowest/highest score) were defined as ex-
ceeding standards, and those with floor and ceiling effect N15%
were defined as failing to meet standards [23].
3.3. Construct validity
Independent sample t-tests were conducted to test whether
the scale scores could differentiate between sex and BMI
groups. One-way analyses of variance (ANOVA) between
groups were conducted to test whether the scale scores could
differentiate between age groups and disease severity groups.
4. Results
4.1. Reliability
The internal consistency or reliability of each scale is shown
in Table 1. The Chronbach's α coefficients ranged from 0.54 to
0.95 with the majority of the coefficients N0.70 (Table 1). The
test–retest reliability with Spearman's correlation ranging from
0.42 to 0.88 is also shown in Table 1.
Floor and ceiling effects were analyzed. The majority of the
responses were in the mid-range. All of the scales met standards
for floor effect but five of the scales failed to meet standards for
ceiling effect (Table 1).
4.2. Construct validity
To test whether the CFQ-R14+ scales could differentiate
between participants concerning disease severity, patients were
divided into three groups according to pulmonary function —
mild disease severity (N=95), moderate disease severity (N=60)
and severe disease severity (N=24). Differences between the
three disease severity groups are shown in Table 2. In all the
CFQ-R+14 scales, except for the scale of digestive symptoms
higher scores were associated with milder disease severity.ing effects on the CFQ-R14+
an's Sig. value
(2-tailed)
Floor effects
(% min score of 0)
Ceiling effects
(% max score of 100)
0.008 ⁎ 1.5 23.2
0.068 1.0 19.8
0.052 2.1 4.1
0.00 ⁎ 0.0 10.3
0.139 0.0 5.6
0.11 2.6 27.7
0.00 ⁎ 1.5 62.8
0.006 ⁎ 1.0 4.1
0.00 ⁎ 3.6 13.3
0.00 ⁎ 9.9 62.5
0.007 ⁎ 0.5 5.2
0.028 ⁎⁎ 0.0 12.9
Table 2
Mean scale scores on CFQ-R14+ compared to level of pulmonary function
Mild FEV1≥71% (mean±S.D.) Moderate FEV1 41–70% (mean±S.D.) Severe FEV1≤40% (mean±S.D.) F-value
Physical functioning 85.8±18.5 71.7±25.0 44.5±31.2 32.01 ⁎
Role limitations 85.9±15.1 77.6±19.0 69.7±29.2 8.46 ⁎
Vitality 62.4±20.6 56.9±14.6 47.8±23.9 5.71 ⁎
Emotional functioning 78.3±18.4 70.6±19.9 67.0±21.3 4.77 ⁎
Social functioning 76.8±14.8 72.7±15.9 67.1±16.0 4.22 ⁎⁎
Body image 83.0±19.0 69.6±25.5 56.0±29.9 15.46 ⁎
Eating disturbances 90.1±22.4 86.9±20.3 74.8±28.7 4.39 ⁎⁎
Treatment burden 60.0±23.4 56.1±20.4 42.4±27.0 5.66 ⁎
Health perceptions 68.4±27.0 55.5±21.5 40.7±31.4 12.41 ⁎
Weight problems 89.6±22.5 74.7±34.4 43.1±38.7 24.60 ⁎
Respiratory symptoms 75.5±19.2 66.3±18.3 48.1±23.3 19.52 ⁎
Digestive symptoms 75.1±18.7 72.7±18.6 74.5±18.7 0.31
* Correlation is significant at the 0.01 level (2-tailed).
** Correlation is significant at the 0.05 level (2-tailed).
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malnourished (N=49) participants (Table 3). The nourished
group scored significantly higher on all the CFQ-R+14 scales
except on the scales of vitality, social functioning and digestive
symptoms. On these scales there was a tendency towards higher
CFQ-R+14 scores in the nourished group.
Comparisons were made between males (N=83) and females
(N=97) and no significant differences in scores were found in
any of the scales.
Participants were divided in age groups: adolescents (N=40),
young adults (N=56) and adults (N=84). We found no
significant age-related differences.
5. Discussion
The aim of the current study was to assess the validity and
reliability of the Danish version of the CFQ-R+14. Our results
indicate that the CFQ-R+14 for most scales is a reliable and
valid tool to measure health-related quality of life in adolescents
and adults with CF.
Comparisons of participants with non-responders showed no
significant differences in BMI but significant differences inTable 3
Mean scales scores on CFQ-R14+ compared to nutritional status
Nourished BMI≥19 (mean±S.D.)
Physical functioning 79.9±22.1
Role limitations 84.3±16.1
Vitality 60.2±18.6
Emotional functioning 76.0±19.2
Social functioning 75.4±15.4
Body image 81.9±19.3
Eating disturbances 89.5±21.5
Treatment burden 58.7±21.9
Health perceptions 63.0±26.3
Weight problems 87.1±26.1
Respiratory symptoms 71.1±19.9
Digestive symptoms 74.4±18.5
* Correlation is significant at the 0.01 level (2-tailed).
** Correlation is significant at the 0.05 level (2-tailed).FEV1, sex and age. The non-responders were older, there were
more males and FEV1 was lower. The difference in sex is
common and the difference in age might be explained by the
possibility that the parents remind the younger patients to fill in
the questionnaire. The difference in FEV1 could be explained by
the fact that it requires some energy to face the problems and the
limitations that some patients with low FEV1 might have. It
must be considered as a weakness in this study. Comparison
with similar studies was not possible because of lack of data on
the non-responders.
The internal consistency was good with the majority of the
scales being higher than 0.7 (Chronbach's α), two of the scales
were slightly lower (body image 0.67, digestive symptoms
0.64) and the scale on social functioning was 0.54. Our results
are comparable with the results of other studies [14,17,18]
though the scale of social functioning was higher than 0.6 in
those studies.
Eight of the scales did not show adequate test–retest stability.
The test–retest reliability is especially important when a scale is
used to assess the progress of treatment. If a scale is not stable,
then it is impossible to determine whether measured change
is real or represents random error in the scale [22]. The poorMalnourished BMIb19 (mean±S.D.) t-value
65.2±33.2 −2.86 ⁎
72.0±24.9 −3.18 ⁎
54.3±22.3 −1.78
69.2±20.2 −2.04 ⁎⁎
70.4±15.9 −1.94
56.7±28.5 −5.71 ⁎
80.6±25.9 −2.14 ⁎⁎
49.7±26.5 −2.11 ⁎⁎
51.9±30.5 −2.40 ⁎⁎
54.6±38.3 −5.37 ⁎
62.0±24.1 −2.35 ⁎⁎
73.3±19.5 −0.35
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or of the possibility that the patients were not clinically stable in
spite of no change in their basic treatment.
Floor effects were small, but five of the twelve scales failed
to meet standards for ceiling effects. Thus the scales of physical
functioning, role limitations, body image, eating disturbances
and weight problems had poor sensitivity for change and for
patients scoring at the top of the scales. In the American vali-
dation high ceiling effects were found on three of those scales
(eating disturbances 60.6%, body image 28.8% and physical
functioning 19.7%). This might indicate that an alteration of
these scales should be considered.
Similar to previous studies [14,16] we found that quality of
life measured by the CFQ-R+14, except from few of the
subscales was, significantly associated with FEV1 and BMI.
This is an indication of the construct validity of the CFQ-R+14 in
a Danish context. The lack of association between the subscales
of digestive symptoms and disease severity was expected.
Patients with low FEV1 might have no digestive problems and
patients with high FEV1 might have significant digestive
problems.
Contrary to what could be expected and findings of others
[14,18], we found no differences in CFQ-R+14 between age
groups although disease is progressing with age. The reason
might be that the oldest patients are not necessarily the most
severely ill. Among the patients in our study 46.7% (N=84)
were N25 years, but only 13.4% (N=24) of the patients had
severe disease (FEV1≤40% of predicted).
Gender differences in morbidity and mortality between male
and female CF patients are well-documented [24,25] but our
study did not corroborate these findings. Females demonstrated
lower, though not significant, CFQ-R+14 scores than males in
all scales except respiratory symptoms, body image and weight.
This is consistent with other studies [26,27] where females
demonstrated higher satisfaction with low weight than males.
In conclusion the internal reliability of the Danish CFQ-R+14
was acceptable in all except three subscales. When conducting
intervention studies the low test–retest correlations of four sub-
scales have to be taken into consideration, and the sensitivity of
the eating disturbances and weight problem subscales need to be
further investigated.
The CFQ-R+14 can be used for many purposes. Firstly, it
ought to be used in the investigation of any new treatment.
Secondly, it could be used in daily clinical practice as a tool to
decide on the most important topics for the patient to discuss
with the physician. The CFQ-R+14 could be used routinely in
connection with outpatient visits; the physician could use the
patient's CFQ-R+14 answers as a starting point for the com-
munication with the patient. Thirdly, the CFQ-R+14 could be
used to follow the patients' quality of life over time. This would,
however, require a validation of the CFQ-R for children and their
parents; a process we hope to initiate in the immediate future.
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